

**Supplemental Table 1.** Clinical characteristics of RMD participants stratified by vaccine type (mRNA or J&J)

	<b>mRNA (n=994)</b>	<b>J&amp;J (n=45)</b>	<b>p-value</b>
Age, median (IQR)	46.3 (37, 58)	47.3 (41, 56)	0.47
Male sex, no. (%)	58 (5.8%)	6 (13.3%)	0.08
Days from D2 to testing, median (IQR)	29.0 (28.0, 33.0)	29.0 (28.0, 32.0)	0.81
Non-white, no. (%)	104 (10.5%)	1 (2.2%)	0.25
Diagnosis, no. (%)			0.23
Inflammatory arthritis <sup>1</sup>	442 (44.5%)	19 (42.2%)	
Overlap connective tissue disease <sup>2</sup>	213 (21.5%)	7 (15.5%)	
Systemic lupus erythematosus	206 (20.7%)	10 (22.2%)	
Sjögren's syndrome	49 (4.9%)	7 (15.5%)	
Myositis	53 (5.3%)	1 (2.2%)	
Vasculitis <sup>3</sup>	21 (2.1%)	1 (2.2%)	
Systemic sclerosis	10 (1%)	0 (0%)	
Therapy included in regimen, no. (%) <sup>4</sup>			
Azathioprine	77 (7.7%)	1 (2.2%)	0.36
Hydroxychloroquine	414 (41.6%)	16 (35.5%)	0.42
Leflunomide	47 (4.7%)	4 (8.8%)	0.13
Methotrexate	255 (25.7%)	12 (26.6%)	0.85
Tacrolimus	15 (1.5%)	1 (2.2%)	0.46
Mycophenolate	145 (14.6%)	4 (8.8%)	0.64
Abatacept	38 (3.8%)	1 (2.2%)	>0.9
Belimumab	114 (11.5%)	6 (13.3%)	0.80
Interleukin inhibitor <sup>5</sup>	67 (6.7%)	2 (4.4%)	>0.9
Rituximab	58 (5.8%)	4 (8.8%)	0.29

TNF inhibitor	239 (24.0%)	9 (20.0%)	0.71
Tofacitinib	62 (6.2%)	2 (4.4%)	>0.9
Glucocorticoids <sup>6</sup>	295 (29.7%)	10 (22.2%)	0.38
Immunomodulatory <sup>7</sup>	47 (4.7%)	1 (2.2%)	>0.9
Combination therapy <sup>8</sup>	517 (52.0%)	19 (42.2%)	0.59

**1** Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis

**2** Denotes a combination of two or more of the rheumatic conditions

**3** Polyarteritis nodosa, Behcet's syndrome, polymyalgia rheumatica, temporal arteritis, eosinophilic granulomatosis polyangiitis, granulomatous polyangiitis, Henoch-Schonlein purpura, microscopic polyangiitis, or Takayasu arteritis

**4** Participants could select more than 1 option thus sum is greater than 100%

**5** Interleukin inhibitors include ixekizumab, secukinumab, tocilizumab and ustekinumab.

**6** Glucocorticoids includes prednisone and prednisone equivalents.

**7** Immunomodulatory includes intravenous immunoglobulin (IVIg) and subcutaneous Immunoglobulin (SCIg).

**8** Denotes a combination of conventional DMARD, biologic, corticosteroid, or immunomodulatory therapy